Dublin –(Business Wire)–The “Global Insulin Drugs and Delivery Technologies Market” report has been added to ResearchAndMarkets.com’s supply.
This report will deeply explore the Insulin Drugs and Delivery Technologies market. This report analyzes the market trends of Insulin Drugs and Delivery Technology using 2021 data, 2022 estimates, CAGR forecast to 2027 (forecast period 2022-2027), and regional markets for Insulin Drugs and Delivery Technology .
This report will highlight the current and future market potential of insulin drugs and delivery technologies and provide a detailed analysis of the competitive environment. This report will cover regulatory scenarios, drivers, constraints and opportunities. The report also covers market forecasts and market shares of key market players to 2026.
Insulin drugs and delivery technologies are used to treat both type 1 and type 2 diabetes. Convenient insulin delivery devices such as smart pens can help people with diabetes optimize blood sugar control and minimize the risk of related health problems. Advanced insulin delivery devices provide better patient compliance.
Traditional syringes and insulin pumps are being replaced by reusable and disposable insulin pens, which combine portability, greater dose accuracy, built-in memory, larger doses and ease of use. There are no major breakthroughs from traditional syringes and pumps.
Major manufacturers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. Major manufacturers of modern and human insulins include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International Ltd, Biocon and Viatris Inc.
The market growth is attributed to factors such as increasing incidence of diabetes and novel insulin drugs and delivery technologies. The global market for insulin drugs and delivery technologies is segmented by device type, insulin type, and region.
In this report, the market has been segmented on the basis of device type, insulin type, and geographic region. Device types include syringes, insulin pens, insulin pumps, smart pens, and more. Insulin types include long-acting, rapid-acting, premixed, intermediate-acting, and short-acting.
Geographical regions covered include North America, Europe, Asia Pacific and Rest of World (RoW). Individual countries covered include the US, Germany, UK, Italy, France, Japan, China and India.
Descriptive company profiles of major manufacturers of modern insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen
report includes
-
24 data sheets and 31 additional sheets
-
Latest Review of Global Insulin Drugs and Delivery Technology Market
-
Global market trend analysis including historical market revenue (sales data) for 2020 and 2021, estimates for 2022, and compound annual growth rate (CAGR) forecast to 2027
-
Current status of the insulin drug and delivery industry structure, new technology updates and issues surrounding insulin pens and insulin syringes, ongoing research activities and highlights of regulatory and pricing scenarios
-
Estimation of actual market size and market forecasts for insulin drugs and delivery technologies, along with corresponding market share analysis by device type, insulin type, and geographic region
-
The latest on major M&A transactions, partnerships, collaborations and other strategic alliances within the insulin drug and delivery technology industry
-
Porter’s five forces analysis model that comprehensively considers micro and macro environmental factors prevalent in the market to analyze market opportunities
-
Identify key stakeholders and analyze the competitive landscape based on recent developments and segment revenue
Key topics covered:
Chapter 1 Introduction
1.1 Overview of insulin
1.2 Overview of Diabetes
1.2.1 Disease symptoms and risk factors
1.2.2 Epidemiology and economic burden
1.3 Research goals and objectives
1.4 Reasons for conducting this study
1.5 What’s new in this update?
1.6 Scope of the report
1.7 Sources of information
1.8 Methodology
1.9 Geographical Distribution
1.10 Analyst Certificate
1.11 Custom Studies
1.12 Related research reports
Chapter 2 Summary and Key Points
Chapter 3 Market Dynamics
3.1 Market Drivers
3.1.1 Rising prevalence of diabetes
3.1.2 Intelligent insulin delivery technology
3.1.3 Painless insulin delivery technology
3.2 Market Restrictions
3.2.1 Product recall
3.3 Market Opportunities
3.3.1 Inorganic Strategies of Market Participants
Chapter 4 Market Overview
4.1 Market Insights
4.1.1 Insulin
4.1.2 Diabetes
4.2 Current market trends
4.2.1 Recent Product Introduction
4.2.2 Recent strategic alliances
4.3 Future Outlook
Chapter 5 Regulatory Environment and Reimbursement Options
5.1 Regulatory environment
5.1.1 US Medical Device Regulations
5.1.2 US Drug Regulations
5.1.3 European Medical Device Regulations
5.1.4 European Medicines Regulations
5.1.5 Asia Pacific Medical Device Regulations
5.2 Reimbursement scenarios
5.2.1 Pricing and Reimbursement Overview
5.2.2 Pricing and Reimbursement of Medical Devices
5.2.3 Drug Pricing and Reimbursement
5.3 Insurance
5.3.1 Diabetes Emergency Insurance
Chapter 6 Covid-19 Impact on the Market
6.1 Overview
6.2 Covid-19 crisis
6.2.1 Impact on Insulin Drugs and Delivery Technology Market
6.2.2 Covid-19 measures
Chapter 7 Market Segmentation by Device Type
7.1 Insulin Delivery Technology
7.1.1 Side ring
7.1.2 Insulin Pens
7.1.3 Insulin Pumps
7.1.4 Smart Pen
7.1.5 Others
Chapter 8 Market Segmentation by Insulin Type
8.1 Insulin
8.1.1 Insulin structure
8.1.2 Insulin Biosynthesis
8.1.3 Types of insulin
Chapter 9 Market Segmentation by Regions
9.1 Overview
9.1.1 North America
9.1.2 Europe
9.1.3 Asia Pacific
9.1.4 Rest of the World
Chapter 10 Market Opportunity Analysis
10.1 Porter’s Five Forces Analysis
10.1.1 Threat of new entrants
10.1.2 Threat of Substitutes
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining power of buyers
10.1.5 Degree of competition
Chapter 11 Competitive Landscape
Chapter 12 Company Profile
12.1 Major Companies
-
B. Braun Melsungen AG
-
Becton, Dickinson and Co.
-
Biocon
-
Boehringer Ingelheim International Ltd.
-
Eli Lilly
-
F. Hoffmann-La Roche Ltd.
-
Medtronic
-
Novo Nordisk A/S
-
Sanofi
-
Viatris Inc.
-
Ypsomed Holdings
-
other companies
-
simplicity
-
Tecsun Technology Saturday
-
Emperra GmbH eHealth Technology
-
insulin company
-
Nanopass Technologies Ltd.
-
Nipro Medical Corporation
-
irving mumford co., ltd.
-
Tandem Diabetes Care Inc.
For more information on this report, please visit https://www.researchandmarkets.com/r/paod2q